Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

Oral use of the selective FLT3 kinase inhibitor gilteritinib in patients who had relapsed or refractory acute myeloid leukemia with FLT3 mutations led to a median overall survival of 9.3 months (vs. 5.6 months with standard chemotherapy) and complete remission with full or partial hematologic recove...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 381; no. 18; pp. 1728 - 1740
Main Authors Perl, Alexander E, Martinelli, Giovanni, Cortes, Jorge E, Neubauer, Andreas, Berman, Ellin, Paolini, Stefania, Montesinos, Pau, Baer, Maria R, Larson, Richard A, Ustun, Celalettin, Fabbiano, Francesco, Erba, Harry P, Di Stasi, Antonio, Stuart, Robert, Olin, Rebecca, Kasner, Margaret, Ciceri, Fabio, Chou, Wen-Chien, Podoltsev, Nikolai, Recher, Christian, Yokoyama, Hisayuki, Hosono, Naoko, Yoon, Sung-Soo, Lee, Je-Hwan, Pardee, Timothy, Fathi, Amir T, Liu, Chaofeng, Hasabou, Nahla, Liu, Xuan, Bahceci, Erkut, Levis, Mark J
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 31.10.2019
Subjects
Acute myeloid leukemia
Administration, Oral
Adult
Aged
Aged, 80 and over
Aniline Compounds - adverse effects
Aniline Compounds - therapeutic use
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Chemotherapy
Death
Drug Resistance, Neoplasm
Female
Flt3 protein
fms-Like Tyrosine Kinase 3 - genetics
Follow-Up Studies
Humans
Laboratories
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - mortality
Liver - drug effects
Male
Medical prognosis
Middle Aged
Mutation
Myeloid leukemia
Neutropenia
Pharmaceuticals
Protein-tyrosine kinase
Pyrazines - adverse effects
Pyrazines - therapeutic use
Recurrence
Remission
Remission (Medicine)
Remission Induction
Salvage Therapy
Survival
Survival Analysis
Thrombocytopenia
Online AccessGet full text

Cover

More Information
Summary:Oral use of the selective FLT3 kinase inhibitor gilteritinib in patients who had relapsed or refractory acute myeloid leukemia with FLT3 mutations led to a median overall survival of 9.3 months (vs. 5.6 months with standard chemotherapy) and complete remission with full or partial hematologic recovery in 34.0% of patients (vs. 15.3%).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1902688